



# Royal College of Physicians

## David Chiswell Biography

Dr Chiswell has over 30 years' experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001, and was subsequently sold to AstraZenca where it forms an important part of their biopharmaceutical franchise.

Since leaving CAT in 2002, he has focused on the development of early-stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and as CEO of Nabriva Therapeutics (2009 to 2012). Dr Chiswell currently serves as chairman of Albireo Pharma and is a director of Nabriva Therapeutics. He is a past chairman of the UK Bio Industry Association (BIA) and in 2006 he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.

## Presentation Summary

**Topic:** A view on the future of protein, cell and gene based therapies

Biological molecules, particularly antibodies, have made significant impacts in medicine over the last 20-30 years. The history of monoclonal antibodies from Kohler and Milstein's Nobel winning discovery in 1975 to the 68 monoclonal antibodies currently approved for therapeutic use shows not only how long it takes to turn ideas into approved drugs, but demonstrates the impact that new technologies can have.

More recently the biological arsenal available to clinicians has been augmented by cell and gene based therapies. Can we use what is being researched now and what is being funded by companies and venture capital to provide insights into what changes these new approaches might make to clinical practice over the next 20 years and more